GlassScriptPhysician profile
Benjamin David Gill
NPI 1356801435
$22,081.76
in general payments reported to CMS, 2019-2025
33 companies · $10K in 2025
The $10K reported for 2025 was more than what 94% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.00 · 2021: $18.20 · 2022: $597 · 2023: $4,554 · 2024: $6,744 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $9,258 · Education: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,415.99 |
| Travel and Lodging | $9,258.24 |
| Education | $766.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,689.66 | 2023-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Abbott Laboratories | $4,242.54 | 2023-2025 | Proclaim, Eterna, Octrode |
| Boston Scientific Corporation | $3,312.37 | 2024-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Nevro Corp. | $1,887.76 | 2023-2024 | Senza, Omnia |
| Spr Therapeutics, INC | $590.36 | 2022-2025 | Sprint Pns System |
| Conetic Solutions, INC. | $485.95 | 2025 | |
| Arthrex, INC. | $482.45 | 2025 | |
| Spinal Simplicity, LLC | $388.13 | 2022 | |
| Saluda Medical Americas, INC. | $318.09 | 2024-2025 | Evoke |
| Pacira Pharmaceuticals Incorporated | $300.18 | 2023 | Iovera |
| Vertos Medical, INC. | $296.08 | 2023-2024 | Mild Device Kit |
| Mml US, INC. | $285.26 | 2024-2025 | Reactiv8 |
| Curonix LLC | $257.53 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $199.29 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $188.45 | 2022-2023 | Dysport |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brixton Biosciences, INC. | $159.78 | 2025 | Neural Ice |
| Piramal Critical Care | $120.14 | 2025 | |
| Si-Bone, INC. | $103.97 | 2024-2025 | |
| Pfizer INC. | $95.40 | 2024 | |
| Stryker Corporation | $93.02 | 2023 | Spinejack, Optablate, Omnicurve |
| Tersera Therapeutics LLC | $92.26 | 2024-2025 | Prialt |
| Relievant Medsystems, INC. | $75.68 | 2023 | Intracept |
| Globus Medical, INC. | $75.29 | 2025 | Senza, Omnia |
| Vertex Pharmaceuticals Incorporated | $73.25 | 2024-2025 | |
| Bioventus LLC | $64.06 | 2025 | Stimrouter Implantable Kit |
| Nalu Medical, INC. | $33.79 | 2025 | Nalu Neurostimulation System |
| Forte Bio-Pharma LLC | $31.00 | 2025 | Prolate, Tanlor, Nalocet |
| Protega Pharmaceutials INC | $22.37 | 2025 | Roxybond |
| Indivior INC. | $21.24 | 2024 | Sublocade |
| Collegium Pharmaceutical, INC. | $19.54 | 2024 | Xtampza |
| Allergan, INC. | $18.20 | 2021 | |
| Averitas Pharma INC. | $17.16 | 2024 | Qutenza |
| Biotronik Nro, INC. | $16.51 | 2025 | Prospera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.